Insider Trading Arrangements |
3 Months Ended | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2025
shares
| |||||||||||||||||||||||||||||||||
| Trading Arrangements, by Individual | |||||||||||||||||||||||||||||||||
| Material Terms of Trading Arrangement | Rule 10b5-1 Trading Arrangements From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into or terminate Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended June 30, 2025, our officers or directors adopted, modified, or terminated such trading arrangements as set forth below.
|
||||||||||||||||||||||||||||||||
| Robert Doebele | |||||||||||||||||||||||||||||||||
| Trading Arrangements, by Individual | |||||||||||||||||||||||||||||||||
| Name | Robert Doebele, MD, Ph.D. | ||||||||||||||||||||||||||||||||
| Title | Chief Medical Officer | ||||||||||||||||||||||||||||||||
| Rule 10b5-1 Arrangement Terminated | true | ||||||||||||||||||||||||||||||||
| Termination Date | April 3, 2025 | ||||||||||||||||||||||||||||||||
| Expiration Date | August 3, 2026 | ||||||||||||||||||||||||||||||||
| Arrangement Duration | 488 days | ||||||||||||||||||||||||||||||||
| Aggregate Available | 45,000 | ||||||||||||||||||||||||||||||||